JIA Flashcards
JIA
Most common form of chronic arthritis in childhood
S/S: joint swelling, pain, and limited mobility = restricts child’s participation in activities
JIA classifies all forms of arthritis that begin before age 16, persist longer than 6 weeks, and are of unknown cause
JIA represents and exclusion dx
Role of PT and Goals of PT
Complete a comprehensive exam: identify impairments and determine relationship to observed or reported participation/activity restrictions
Goal of PT: reduce functional impairment, prevent secondary problems, improve activity and participation levels
Interventions must be balanced in rest and exercise
Provide guidelines for choosing activities
Role of PT varies on stage and progression of disease and care setting
Diagnosis and Classification
3 systems used: ACR (american), EULAR (european), and ILAR (international)
No definitive lab tests: DX is made based on clinical presentation
Systemic Arthritis
4-17% of cases
Onset age: throughout childhood, no preferential onset
F = M
Dx marker = spiking a fever of 102.2 or higher that occurs 1-2x daily (morning or evening) for at least 2 weeks with a rapid return to normal or below between spikes
Fever is accompanied by rash found on trunk or limbs, may be seen on face, palms, and soles of feet
Other systemic signs: pleuritis, pericarditis, myocarditis, hepatosplomegaly, and lymphadenopathy
Systemic disease may precede arthritis by several months or years
Systemic signs often subside after initial disease period may recur during exacerbation periods
Oligoarthritis: age of onset, sex ratio, presentation
AKA pauciarticular
27-56% of cases
Onset age: early childhood, peak at 2-4 y/o
F»_space;> M
low grade inflammation in 4 or fewer joints, joint is swollen and warm, not always painful
knee > ankle > elbows
Does not affect hips and small joint of hands
Limited systemic signs, 30% of children develop iridocyclitis (eye inflammation that can lean to functional blindness)
Rx: systemic or topical corticosteroids for inflammation control
Polyarthritis: age of onset, sex ratio, presentation
Rh +
Rh-
Rh +: 2-7%, later childhood or adolescence, F»_space; M, follows disease course similar to RA in adults, may have rheumatoid nodules
Rh-: 11-28%, biphasic distribution, early peak at 2-4 years, later peak at 6-12 years, F»_space; M, nodules less common, fewer joints affected
Arthritis in 5 or more joints
Insidious onset with arthritis progressively noted in more joints
Symmetrical and affects both large and small joints
Can include the cervical spine and TMJ
Joints are swollen and warm
Systemic signs: low grade fever, mild to moderate hepatosplenomegaly and lymphadenopathy
some develop iridocyclitis
persistent arthritis may cause: juxta-articular osteopenia, mm atrophy, weakness, contractures and growth disturbances
Enthesitis- related Arthritis: age of onset, sex ratio, presentation
3-11%
late childhood or adolescence
M»_space; F
Psoriatic Arthritis: age of onset, sex ratio, presentation
2-11%
biphasic distribution, early peak at 2-4 years, later peak at 9-11 years
F > M
Primarily involves distal joints oh hands with psoriasis, usually mild but may lead to general joint destruction
Educate on joint protection
Secondary clinical manifestions
limited joint motion, soft tissue contracture
fatigue
decreased aerobic capacity, reduced excercise tolerance
growth abnormalities (local and general)
osteopenia, osteoporosis and result of long term use of oral steroids
difficulty with ADL’s
possible activity/participation restrictions
gait deviations
Undifferentiated arthritis: age of on set, sex ratio, presentation
11-21% of cases
No specific age of onset or sex ratio
Undifferentiated arthritis: age of on set, sex ratio, presentation
11-21% of cases
No specific age of onset or sex ratio
Incidence and Prevalence
Affects girls more than boys
Between 2-20 per 100,000 at risk in US
Origin and Pathogenesis
Poorly understood, but includes both genetic and environmental components
Autoimmune inflammatory disorder activated by an external trigger in a genetically predisposed host
A viral or bacterial infection precedes disease onset
Suspected genetic predispositions found in MHC region of chromosome 6
Medical Mgmt: Pharmacologic intervention NSAIDS Methotrexate Sulfasalazine Steroids
Want to control arthritis to prevent joint erosion and manage extra articular manifestations
NSAIDS: first line therapy, naproxen, tolmetin, IBU, do not alter disease course treat symptoms
Adverse effects: GI irritation
Methotrexate: m/c disease modifying antirheumatic drug (DMARD) used of poly and systemic JIA
Oral med 1x per week
Monitor liver enzymes due to risk for liver toxicity
Pt with poor prognosis and failure to respond to methotrexate are treated with biological meds that target tumor necrosis factor (cytokine responsible for inflammation)
Entanercept, infliximab, and adalimumab
Sulfasalazine: oligo, DMARD, high risk for toxicity
Systemic glucocorticoid used in systemic who do not respond to other therapies
Steroids do not alter disease course but have potent anti inflammatory effect
Adverse effects: cushings, DM, osteoporosis, myopathy, growth disturbance, obesity, increased susceptibility to infection
Prognosis
Poor articular and functional outcomes in systemic and poly are linked to hip involvement in 1st year of disease
Oligo = best prognosis for joint preservation and function but may develop contractures later on, high risk for eye involvement
Better prognosis associated with early and effective rx to prevent or minimize adverse outcomes